Company: HURA
Filing Date: 2025-06-12
Form Type: 8-K
Source: 0000950170-25-085116
Chunk: 1

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-12
Form: 8-K
Item: Item 5.02
Chunk 1
---
 2024.

(5) Mr. Hoffman, the Company’s former President, Chief Executive Officer and Interim Chief Financial Officer, and TuHURA were parties to a certain Executive Employment Agreement dated November 8, 2021 (the “ Hoffman Employment Agreement”). On October 4, 2024, prior to the completion of the

DOCPROPERTY DOCXDOCID DMS=NetDocuments Format=<< ID>>.<< VER>> \* MERGEFORMAT 4910-9780-3851.3

reverse merger transaction with Kintara Therapeutics, Inc. (the “ Kintara Merger”), the Company entered into an amendment to the Hoffman Employment Agreement (the “ Hoffman Amendment”), pursuant to which, all outstanding stock options previously granted to Mr. Hoffman vested in full on October 4, 2024 in exchange for Mr. Hoffman agreeing to extend the non-competition restrictions of the Hoffman Employment Agreement for a period of twelve months following the date that his employment terminates. Mr. Hoffman’s employment was terminated on October 18, 2024 in connection with the completion of the Kintara Merger. Mr. Hoffman was appointed to the Board in connection with the completion of the Kintara Merger.

(6) The amounts included in the column above reflect (i) cumulative payment of $1,307,014 in severance payable to Mr. Hoffman pursuant to the Hoffman Employment Agreement and (ii) $19,002 in taxable compensation received upon the vesting and conversion of restricted stock units.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

  Exhibit No.                                                                                    
  104              Cover Page Interactive Data File (embedded within the Inline XBRL document).